The organization focuses on managing cost and quality in radiology, musculoskeletal, physical medicine, and genetics.
Deal consideration includes $650 million at the close plus additional contingent consideration of up to $150 million based on 2023 performance.
The upfront consideration will be partly funded by $250 million in Evolent shares issued at $29.50, a 24% premium to the prior day's closing price.
Upon close, the NIA team and platform will be fully integrated into Evolent's value-based specialty care business, which includes New Century Health, Vital Decisions, and IPG.
NIA has revenues of approximately $250 million and a standalone adjusted EBITDA of approximately $50 million.
The transaction is anticipated to be immediately accretive to adjusted EBITDA margins and cash flow.
Highly complementary business is expected to add $85 million of high-visibility Adjusted EBITDA by 2024.
Diversifies Evolent's revenue base and increases cross-sell opportunity from $16 billion to $50 billion.
In addition to the NIA acquisition, Evolent and Centene are expanding Centene's relationship with NIA and extending NIA's contracts with Centene through 2027. These expansions will generate at least $20 million of Adjusted EBITDA by the fourth quarter of 2024.
Price Action: EVH shares closed at $23.86 on Thursday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.